Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.